Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 120, Issue 4-5, 2010, Pages 164-171

  Jawaid, Kiran ^a   Crane, Smiley R ^a   Nowers, Jennifer L ^a   Lacey, Michael ^a   Whitehead, Saffron A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Breast cancer cells; Cyclin D1; Epigenetics; Genistein; Growth; Histone 3; Histone deacetylase inhibitors; Pro caspase 9

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APICIDIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR; ESTRADIOL; GENISTEIN; HISTONE H3; PROCASPASE 9; TRICHOSTATIN A; VALPROIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPIGENETICS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LONG TERM EXPOSURE; PROTEIN EXPRESSION;

ACETYLATION; ANTICARCINOGENIC AGENTS; BREAST NEOPLASMS; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MITOGENS;

EID: 77953608981     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2010.04.007     Document Type: Article

References (39)

1. Trock B.J., Hilakivi-Clark L., Clarke R. Meta-analysis of soy intake and breast cancer risk. J. Natl. Cancer Inst. 2006, 98:459-471.
2. Wu A.H., Yu M.C., Tseng C.C., Pike M.C. Epidemiology of soy exposure and breast cancer risk. Br. J. Cancer 2008, 98:9-14.
3. Warri A., Saarinen N.M., Makela S., Hilakivi-Clarke L. The role of early life genistein exposures in modifying breast cancer risk. Br. J. Cancer 2008, 98:1485-1493.
4. Lopez J., Percharde M., Coley H.M., Webb A., Crook T. The context and potential of epigenetics in oncology. Br. J. Cancer 2009, 100:571-577.
5. Baylin S.B., Esteller M., Rountree M.R., Bachman K.E., Schuebel K., Herman J.G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 2001, 10:687-692.
6. Park J.H., Jung Y., Kim T.Y., Kim S.G., Jong H.S., Lee J.W., Kim D.K., Lee J.S., Kim N.K., Kim T.Y., Bang Y.J. Class 1 histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumour proliferation. Clin. Cancer Res. 2004, 10:5271-5281.
7. Nakagawa M., Oda Y., Eguchi T., Aishima S., Yao T., Hosoi F., Basaki Y., Ono M., Kuwano M., Tanaka M., Tsuneyoshi M. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 2007, 18:769-774.
8. Krusche C.A., Wulfing P., Kersting C., Vloet A., Bocker W., Kiesel L., Beier H.M., Alfer J. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res. Treat. 2005, 90:15-23.
9. Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., Hamaguchi M., Hara Y., Kobayashi S., Iwase H.H. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. Treat. 2005, 94:11-16.
10. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 2001, 1:194-202.
11. Lo P.K., Sukumar S. Epigenomics and breast cancer. Phamacogenomics 2008, 9:1879-1902.
12. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
13. Anastasius N., Boston S., Lacey M., Storing N., Whitehead S.A. Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway. J. Steroid Biochem. Mol. Biol. 2009, 116:50-55.
14. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal. 2002, 14:381-395.
15. Roy P.G., Thompson A.M. Cyclin D1 and breast cancer. Breast 2006, 15:718-727.
16. Choi E.J., Kim G.-H. Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells. J. Clin. Biochem. Nutr. 2009, 44:260-265.
17. Lin Y.-J., Hou Y.C., Lin C.-H., Hsu Y.-A., Sheu J.J.C., Lai C.-H., Chen B.-H., Chao P.-D.L., Wan L., Tsai F.-J. Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells. Biochem. Biophys. Res. Commun. 2009, 378:683-688.
18. Hsu Y.L., Uen Y.H., Chen Y., Liang H.L., Kuo P.L. Tricetin, a dietary favonoid, inhibits proliferation of human breast adenocarcinoma MCF-7 cells by blocking cell cycle progression and inducing apoptosis. J. Agric. Food. Chem. 2009, 18:8688-8695.
19. Jin S., Zhang Q.Y., Kang X.M., Wang J.X., Zhao W.H. Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway. Ann. Oncol. 2010, 21:263-268.
20. Phiel C.J., Zhang F., Huang E.Y. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. J. Biol. Chem. 2001, 276:36734-36741.
21. Olsen C.M., Meussen-Elholm E.T.M., Roste L.S., Tauboll E. Antiepileptic drugs inhibit cells growth in the human breast cancer cell line MCF-7. Mol. Cell. Endocrinol. 2004, 213:173-179.
22. Hodges-Gallagher L., Valentine C.D., Bader S.E., Kushner P.J. Inhibition of histone deacetylase enhances the anti-proliferative action of antioestrogens on breast cancer calls and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res. Treat. 2007, 105:297-309.
23. Fortunati N., Bertino S., Costantino L., Bosco O., Vercellinatto I., Catalano M.G., Boccuzzi G., Fortunati N., Bertino S., Costantino L., Bosco O., Vercellinatto I., Catalano M.G., Boccuzzi G. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 2008, 259:156-164.
24. WAF1/CIP1 gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells. J. Endocrinol. 2003, 179:41-53.
25. Alao J.P., Lam E.W., Ali S., Buluwela L., Bordogna W., LackeyVarshochi P., Stavropoulou A.V., Coombes R.C., Vigushin D.M. Histone deacetylase inhibitor trichostatin A represses estrogen receptor-dependent transcription and promotes protoeasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin. Cancer Res. 2004, 10(2004):8094-8104.
26. Min K.N., Cho M.J., Kim D.K., Sheen Y.Y. Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells. Arch. Pharm. Res. 2004, 27:554-561.
27. Noh E.J., Lim D.S., Jeong G., Lee S.J. An HDAC inhibitor, trichostatin A, induces a delay at G2/M transition, slippage of spindly checkpoint, and cell death in a transcription-dependent manner. Biochem. Biophys. Res. Commun. 2009, 378:326-331.
28. Kim M.S., Son M.-W., Kim W.-B., Park Y.I., Moon A. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett. 2000, 157:23-30.
29. Im J.Y., Park H., Kang K.W., Choi W.S., Kim H.S. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and negative human breast cancer cells. Chemico-Biol. Interact. 2008, 172:235-244.
30. Momparler R.L. Epigenetic therapy of cancer with 5.aza-2'deoxycytidine (decitabine). Semin. Oncol. 2005, 32:443-451.
31. Bovenzi V., Momparler R.L. Antoneoplastic action of 5-aza-2'deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells. Cancer Chemother. Parmacol. 2001, 48:71-76.
32. Hurtubise A., Momparler R.L. Effects of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-aza-2'deoxycytidine (decitabine) on human breast carcinoma cells. Cancer Chemother. Pharmacol. 2006, 58:618-625.
33. Ateeq B., Unterberger A., Szyf M., Rabbani S.A. Pharmacologica inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008, 10:266-278.
34. Billam M., Sobolewski M.D., Davidson N.E. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res. Treat. 2009, 120:581-592.
35. Chiam K., Tilley W.D., Butler L.M., Bianco-Miotto T. The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. Biochim. Biophys. Acta 2009, 1795:104-109.
36. Dolinoy D.C., Weidman J.R., Waterman R.A., Jirtle R.L. Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect. 2006, 114:567-572.
37. Day J.K., Bauer A.M., desBordes C., Zhuang Y., Kim B.-E., Newton L.G., Nehra V., Forsee K.M., MacDonald R.S., Besch-Williford C., Huang T.H-M., Lubahn D.B. Genistein alters methylation patterns in mice. J. Nutr. 2002, 132:2419S-2423S.
38. Kikuno N., Shiina H., Urakami S., Kawamoto K., Hirata T., Tanaka Y., Majid S., Igawa M., Dahiya R. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int. J. Cancer 2008, 123:552-560.
39. Ehrlich M. Cancer-linked hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 2006, 310:251-274.